So the answer is conditional: the medical and prescription components are usually eligible, while purely behavioral pieces may require a Letter of Medical Necessity
Therefore, these short answers cover the questions people ask most often
The agreement calls for further price reductions over the next two years, and lower prices ($150) for oral GLP-1 medications when they are approved for obesity and become available
No, anemia is not listed as an adverse effect in FDA prescribing information for tirzepatide (Mounjaro or Zepbound), and clinical trials have not identified it as a significant safety concern compared to placebo or other medications
We recommend that you read labels, warnings, and directions of all products before use and not rely solely on the information provided by Ultimate Sup
Rapid weight loss, not GLP-1 medications alone, is the primary driver of skin laxity